Please login to the form below
E coli
This page shows the latest E coli news and features for those working in and with pharma, biotech and healthcare.
WHO report provides data for high levels of antimicrobial resistance in bacteria
Moreover, the report showed that over 20% of E coli isolates – the most common pathogen in urinary tract infections – were resistant to ampicillin and co-trimoxazole, both first-line drugs, and
Latest news
-
GSK to submit drug application for new antibiotic to US FDA
An estimated 150 million people are affected by UTIs each year, with approximately 80% of these cases caused by E coli. ... This provides activity against most strains of E coli and S saprophyticus, including isolates resistant to current antibiotics.
-
Locus Biosciences announces first patient treated in urinary tract infection trial
Around 80% of UTI cases are caused by E coli, often including strains that are antibiotic resistant. ... treatment of urinary tract infections (UTIs) caused by Escherichia coli (E coli) bacteria, the clinical-stage biotechnology company announced.
-
New research shows drug candidate may effectively treat antibiotic-resistant bacteria
One of the modified compounds – fabimycin – proved to be effective against more than 200 drug-resistant clinical isolates of Escherichia coli (E. ... coli), Klebsiella pneumoniae and Acinetobacter baumannii, while remaining ‘relatively inactive’
-
Researchers discover new antibiotic using AI
The research team trained the AI’s neural network to identify molecules that inhibit the growth of the common bacteria Escherichia coli(or E.coli) using a collection of 2, 335 ... The team asked the AI to predict which molecules would work against
-
Danish biotech establishes online scientific collaboration network
coli detection device. Nearly 18, 000 children die each day from diarrhea and other water-related diseases, mainly contracted from contaminated water or food. ... But current detection tests for E. coli bacteria take up to 24 hours to return a result.
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Tackling antimicrobial resistance on multiple fronts
In a British context, the majority of UTIs are due to Escherichia coli (E. ... coli). If we treat E. coli infections incorrectly, over-prescribing first-line antibiotics when some patients may already have resistant infections, we will effectively create
-
Combining therapies and combining research
However, antibiotics for common bacterial infections, for example, staphylococci and Escherichia coli continued to be single molecule therapies. ... coli. The rejuvenation of existing antibiotics using synergistic combinations is likely to be an integral
-
The threat of antimicrobial resistance
The farming industry is also playing a big part in the problem, with investigative journalists uncovering the story that thousands of tonnes of the antibiotic colistin (polymyxin E) were being fed ... Yet colistin resistance is already here and spreading
-
Deal Watch February 2016
coli and influenza, and in toxicology applications. While Abbott already has a significant diagnostics presence with global sales in 2015 in this segment of $4.6bn, it forecasts that the acquisition ... The ARCUS technology enables the production of CAR T
-
Curbing the rise of drug resistance
Focusing on three bacteria and three diseases – Staphylococcus aureus (responsible for MRSA), E. ... coli and Klebsiella pneumoniae, and HIV, tuberculosis and malaria - the paper assesses the impact on GDP of increased mortality and morbidity by 2050,
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
